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VIRAL EXPRESSION OF TSG-6 CAN STIMULATE OSTEOPHYTE
FORMATION IN EXPERIMENTAL OSTEOARTHRITIS
M.G. Broeren, M.B. Bennink, O.J. Arntz, A.B. Blom, W.B. van den Berg,
F.A. van de Loo. Radboud Univ. Med. center, Nijmegen, Netherlands
Purpose: Tumor necrosis factor-inducible gene 6 (TSG-6, also named
TNFAPI6) is upregulated during experimental arthritis in mice (Geurts
et al. 2009). The therapeutic efﬁcacy of TSG-6 has been shown in
multiple animal models for rheumatoid arthritis, reducing bothinﬂammation and cartilage damage. Recent studies suggest that
inﬂammation can also play a role in early osteoarthritis (OA) patho-
genesis (Ayral et al. 2005). Therefore, TSG-6 therapy might also be an
effective treatment in inﬂammatory OA. In this study, we analyzed the
expression of TSG-6 during experimental arthritis and explored the
effects of TSG-6 gene therapy in a murine model of inﬂammatory
osteoarthritis.
Methods: TSG-6 gene expression was determined in microarrays of
collagenase-induced osteoarthritis at day 7 and day 14 after induction.
The murine TSG-6 genewas cloned in a lentiviral and adenoviral vector.
Freshly isolated bone marrow-derived dendritic cells (BMDCs) were
transduced with the lentiviral vector and subsequently differentiated
into osteoclasts on bone slices with M-CSF and RANKL. After 10 days,
bone slices were washed and stained using Coomassie Blue and bone
resorption was determined using the Leica Application Suite software.
To study the effects of TSG-6 in experimental knee osteoarthritis, mice
received two intra-articular injections of collagenase. Four days prior to
and 20 days after arthritis induction, mice were injected intra-articu-
larly with TSG-6 adenovirus. At day 7, inﬂammation was assessed using
ﬂuorescent Prosense probes. At day 42, knee joints were analyzed by X-
ray and histological assessment.
Results: TSG-6 was upregulated in collagenase-induced OA (2,6x at day
7 (P<0.05) and 2.5x at day 14 (P¼0.55)). BMDCs transduced with TSG-6
lentivirus showed strong expression of TSG-6. Bone resorption by
BMDC-derived osteoclasts was signiﬁcantly reduced (20.1% surface
erosion with control virus to 10.4%, p¼0.01), providing a possible
mechanism for the therapeutic effects in rheumatoid arthritis models.
At day 7 of collagenase-induced osteoarthritis, no difference in
inﬂammation was detected using the Prosense probes. At day 42, no
improvement on cartilage damage was seen, but X-ray analysis showed
strong osteophyte formation at the femur/tibia region in the knee joint.
Histological analysis showed that the osteophytes contained both bone
and cartilage.
Conclusions: Viral expression of TSG-6 can reduce the bone resorption
activity by BMDC-derived osteoclasts. The expression of TSG-6 by
synovial cells during experimental osteoarthritis results in the for-
mation of osteophytes. These results imply a causative role for TSG-6 in
osteophyte formation, supporting the recent ﬁnding that TSG-6 activity
is associated with radiographic progression of OA (Wisniewski et al.
2014).
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INTRA-ARTICULAR HYALURONIC ACID DELAYS TOTAL KNEE
REPLACEMENT IN PATIENTS WITH KNEE OSTEOARTHRITIS:
EVIDENCE FROM A LARGE U.S. HEALTH CLAIMS DATABASE
R. Altman y, S. Lim z, R. Steen x, V. Dasa k. yUCLA, Agua Dulce, CA, USA;
z Seikagaku, Tokyo, Japan; xBioventus Global, Durham, NC, USA;
k Louisiana State Univ., New Orleans, USA
Purpose: To evaluate the impact of one or more courses of treatment
with intraarticular (IA) hyaluronate (HA) compared to no IA HA injec-
tions on the time to total knee replacement (TKR) on patients with
osteoarthritis (OA), using a large administrative claims database.
Methods: Retrospective analysis used the IMS PharMetrics Plus claims
database of approximately 79 million patients to identify patients with
OA of the knee who received TKR within a 6 year selection window
(2007-2013). The initial OA diagnosis in the databasewas the index date
and included patients with knee OA who had continuous enrollment
fromOA diagnosis until TKR. Kaplan-Meier survival analysis was used to
measure time-to-TKR. Subsets were deﬁned by the number of courses
of treatment received, ranging from 0 (no IA HA), 1, 2, 3, 4, to 5 HA
courses. Median timewas the time (in years) at which 50% of patients in
a cohort had received TKR. Log-rank tests were used to compare dif-
ferent cohorts.
Results: The database included 182,022 patients with knee OA and TKR.
Of these, 131,673 (72.3%) patients had no HA, and 50,349 (27.7%)
received at least one course of IA HA. Age, sex, and Charlson comor-
bidity scores were similar among subsets. Of those receiving IA HA, a
total of 36,861 patients (73.2%) received 1 HA course, 8893 (17.7%)
received 2 courses, 2,783 (5.5%) received 3 courses, 1052 (2.1%) received
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diagnosis to when 50% of the subset received TKR was signiﬁcantly
longer (p1 year, an average of 9 months longer than those with no IA
HA. Patients who received 5 courses had a delay in TKR by 3.6 years.
Conclusions: Among 182,022 patients with knee OA, those who
received IA HA had a signiﬁcantly longer time before TKR. More courses
of IA HA injections were associatedwith a longer time toTKR. This study
suggests a signiﬁcant clinical beneﬁt from use of IA HA for OA as delay in
time to TKR can have important clinical and economic implications.Median Time from knee OA diagnosis to TKR by number of courses of IA HA
No IA HA 1 2 3 4 5þ
Days to TKR 114 386 648 875 1054 1312
Years to TKR 0.3 1.1 1.8 2.4 2.9 3.6675
EVALUATION OF THE CLINICAL EFFICACY OF AUTOLOGOUS
CONDITIONED SERUM IN PATIENTS WITH COXARTHROSIS
K. Shirokova, S. Noskov, L. Shirokova. Yaroslavl State Med. Univ.,
Yaroslavl, Russian Federation
Purpose: The aim of this open study was a comparative assessment of
the effectiveness of local therapy with autologous conditioned serum
(ACS) and low molecular weight hyaluronic acid (LHA) in patients with
coxarthrosis.
Methods: The study included 60 patients with ﬁrm coxarthrosis in
accordance with ACR criteria at the age of 55,5 ± 8,7. The main group
(ACS treatment) consisted of 33 (55%) persons. Experimental group
(LHA treatment) consisted of 27 patients who are comparable with the
main group patients in terms of age, BMI, radiographic stage, disease
duration and severity of clinical indicators. ACS was prepared in
accordance with established method and injected intraarticularly (2.5
ml twice a week for three weeks). LHA treatment consisted of 3 weekly
intraarticular injections of 40 mg sodium hyaluronate each. All intra-
articular actions were performed with ultrasound control. Treatment
efﬁciency was evaluated after 1,3 and 6 months after treatment, the
following criteria were used: bodily pain dynamics in accordance with
VAS, morning stiffness module and Womac index functional scale, and
Lequesne index. “Area under the curve” (AUC) approach with estima-
tion of treatment efﬁciency prolongation for 6 months (AUC6) was used
for evaluation of clinical effect retention.
Results: A decrease in pain syndrome intensity according to VAS in hip
joints at 1, 3 and 6 months of treatment in both compared groups was
recorded.However, a signiﬁcant regression was observed in the treat-
ment of pain with ACS in comparison with LHA.After 1 month the
decrease of pain severity in accordancewithVASwas comparable (9.1%, p
¼ 0.40), after 3 and 6 months, pain severity was higher in the LHA group
compared with ACS group (þ 52.5%, p ¼ 0.009 and þ 33.1%, p ¼ 0.047
respectively). AUC6 in case of ACS treatmentwas 35,6% (p¼ 0,011) higher
compared with LHA treatment. Extension of the clinical effectiveness
expressed via "morning stiffness" module of the Womac index AUC6
indicatorwas 55.9% (p¼0.003) higher in case of ACS treatment compared
with LHA treatment. Womac functional scale in case of ACS improved
through all three control timepoints (-23.1% -28.5% -39.1%; p ¼ 0.001).
Same dynamics was observed in LHA group as well (-35.6%, -26.4%; p ¼
0.001 and -20.4%; p ¼ 0.005), however after 6 months of monitoring
more signiﬁcant improvement of articular functionwas recorded within
ACS group compared with LHA (18.3%, p ¼ 0.044). The overall clinical
efﬁcacy in accordancewith Lequesne indexwith a six-monthmonitoring
was comparable in both groups, thedifference cameup to8,8% (p¼ 0,65).
Conclusions: Intensity of pain, stiffness, functional status and overall
clinical severity of coxarthrosis signiﬁcantly and consistently decreased
during therapy with ACS and LHA.However, favorable changes of local
therapy with LHAwere inferior in duration of conservation of treatment
effect of ACS.676
REFINEMENT OF PRECLINICAL STUDIES FOR
VISCOSUPPLEMENTATION THERAPY EVALUATION: INTEREST OF
COMPLEMENTARY TECHNIQUES TO EVALUATE CARTILAGE IN A
RABBIT MODEL OF EARLY OSTEOARTHRITIS
S. Kaderli y, E. Chereul z, E. Viguier x, T. Roger x, M. M€oller k,
L. Scapozza k, O. Jordan k, C. Boulocher x. y Sch. of Pharmaceutical Sci.,
Univ. of Lausanne and Geneva, Geneva, Switzerland; zVoxcan, Marcy
l'Etoile, France; xVetAgro Sup, campus veterinaire, Marcy l'Etoile, France;
k1Sch. of Pharmaceutical Sci., Univ. of Lausanne and Geneva, Geneva,
Switzerland
Purpose: One of the major challenges of the viscosupplementation (VS)
therapy is the development of more efﬁcient formulations and, to this
end, the use of animal models of osteoarthritis (OA) is still mandatory.
The assessment of VS efﬁcacy is challenging mainly since its structural
effects are subtle. In order to reﬁne preclinical VS efﬁcacy studies and
reduce the number of animals used, there is a crucial need for more
sensitive and discriminant evaluation tools. In this study, we especially
focused on complementary techniques to evaluate OA cartilage in a
rabbit model of early OA.
Methods: Cranial cruciate ligament transection (ACLT) was performed
in the left knee of white New-Zealand rabbits (n¼12) to induce trau-
matic OA. One week post-ACLT and then weekly for 5 weeks, the
operated knees of 6 rabbits were injected with a hyaluronic acid (HA)
containing commercial formulation (Ostenil®, HA group). One group
was injected with saline (operated-control group, n¼6). The con-
tralateral right knees (n¼8) were used as unoperated-controls. End-
point evaluation was done at the 6th week post-ACLT and included:
gross and histological scoring of cartilage lesions, measurement of
cartilage thickness by Equilibrium Partitioning Iodine Contrast micro-
Computed Tomography (EPIC m-CT) as well as the evaluation of the
surface by Scanning Electron Microscopy (SEM).
Results: Gross and histological scorings showed statistical differences
between operated and unoperated knees; however, no difference
between the HA and operated-control groups was evidenced. SEM
revealed that unoperated-control samples had normal smooth to rough
surfaces with discreet cable-like structures. Cartilage from the operated
knees presented rough surfaces and clearly visible cable-like structures,
which might be the sign of cartilage matrix erosion. Finally, mean car-
tilage thickness and volume measured by EPIC m-CT were comparable
for the 3 groups. Interestingly, the use of the thickness distribution
representation showed clear differences in the intact cartilage occur-
rences (i.e. thickness higher or equal to 0.9 mm). Indeed, intact cartilage
proportion decreased statistically from 20% in the unoperated-control
group to 10% in the operated-control group. In addition, intact cartilage
proportion in the HA treated knees was equivalent to unoperated-
control group, highlighting a moderate efﬁcacy of HA which was
detected neither by histology nor by SEM.
Conclusions:Complementary techniqueswere implemented toevaluate
cartilage lesions in a rabbitmodel of earlyOA in order to reﬁne preclinical
VS efﬁcacy studies. This study points out that classical evaluation tools
(macroscopy and histology) are sensitive enough to discriminate
between cartilage from unoperated and operated groups in early OA but
that EPIC-mCTalsopermits the detection of the subtle structural effects of
HA, validating this technique as a powerful evaluation tool.
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EVIDENCE OF IN VIVO DRUG DELIVERY VIA THE TAT PROTEIN
TRANSDUCTION DOMAIN
A. Hamil y, D. Haudenschild z, S. Dowdy y, R. June x. yUniv. of California,
San Diego, La Jolla, CA, USA; zUniv. of California, Davis, Sacramento, CA,
USA; xMontana State Univ., Bozeman, MT, USA
Purpose: Drug delivery to synovial joints is a major limitation for
developing effective treatments for osteoarthritis (OA). Synovial joint
anatomy includes large pores that allow direct transport between
synovial ﬂuid and fenestrated capillaries. This transport preferentially
selects larger molecules to remain within the joint and exports smaller
